Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study

Abstract

MYO administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion.

A Comparative Study of Metabolic and Hormonal Effects of Myoinositol vs Metformin in Women With Polycystic Ovary Syndrome: A Randomised Controlled Trial

“…Artini et al 8 found that myo-inositol treatment showed significantly lower Testosterone (2.3 nmol/liter vs. 3.4 nmol/liter; 95% CI = 0.07 and 2.1, respectively; P >0.04), similarly to our study. Zacche 5 also showed decrease in testosterone and LH levels after treatment with myoinositol.…”

“…WHR did not decrease significantly in myoinositol group (Table 3). This was in contrast to study by Constantino et al 7 Artini et al 8 found that, in consideration of baseline fasting insulin levels, myo-inositol treatment induced similar changes in both groups but only patients in myoinositol group demonstrated significant reduction in fasting insulin levels (20.3 ± 1.8 to 12.9 ± 1.8 µU/mL, P <0.00001).…”

“…Artini et al 8 also found no side effects or adverse events in any of the study participants receiving myoinositol.…”

Inositols: from physiology to rational therapy in gynecological clinical practice

“…Following the same fashion, recent studies showed the positive effect on hormonal functions and on insulin sensitivity in target tissues of PCOS subjects [15]. Myo-Ins seems to play a crucial role in oocytes, representing about 99% of inositol intracellular pool [2].…”

The Prevention of Gestational Diabetes

“…The beneficial effects of inositol have been also proved on metabolic and hormonal parameters in insulin-resistant women. Indeed, a significant improvement of typical hormonal parameters was observed in PCOS women after MI treatment: decreased LH, FSH, and testosterone circulation levels, and increased SHBG, estrogens and progesterone circulating levels [81][82][83]. Insulin peripheral sensitivity was improved(reduced HOMA-IR index and/or reduction of the AUC of glucose and insulin during an oral glucose tolerance test) as well as markers of cardiovascular risk with a decrement in systolic and diastolic blood pressure, a decrease in plasma triglycerides, an increased in HDL cholesterol, and a decrease in LDL and total cholesterol concentrations [84,85].…”